Ipsen: worldwide licensing agreement with Sutro Biopharma

(CercleFinance.com) - Ipsen announces the signature, with Sutro Biopharma, of an exclusive worldwide licensing agreement for STRO-003, an antibody-small molecule conjugate (ADC) currently in late-stage preclinical development.


This ADC candidate, which is the first to join Ipsen's expanding portfolio, targets the ROR1 tumor antigen, known to be overexpressed in many types of cancer, including hematological malignancies and solid tumors.

STRO-003 has demonstrated efficacy as a single agent and a satisfactory safety profile during its preclinical development in solid tumors and hematological malignancies, the pharmaceutical company says.

Under the agreed terms, Ipsen obtains exclusive worldwide development and commercialization rights, and Sutro Biopharma is eligible for payments of up to $900m.


Copyright (c) 2024 CercleFinance.com. All rights reserved.